MedTrace Logo

Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training

NCT07441915 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-30

No results posted yet for this study

Summary

People with Parkinson's disease are at higher risk of cognitive decline, and current treatments cannot fully prevent this. This study explores non-drug ways to support brain function.

Intervention: Participants will complete a 5-week cognitive training program at home ("brain fitness"). In addition, they will use a sleep device at night that plays soft sounds to improve deep sleep; Half of the participants will actually receive these sounds (auditory stimulation), while the other half will receive a sham (placebo) version - neither the participants nor the researchers will know the group assignment.

Assessments will take place before and after the intervention, and again three months later, including one overnight stay at University Hospital Zurich per assessment.

The goal is to find out whether improving deep sleep can boost the benefits of cognitive training and help slow cognitive decline in Parkinson's disease.

Conditions

Interventions

DEVICE

Phase-Targeted Auditory Stimulation (PTAS)

Participants will receive Phase-Targeted Auditory Stimulation (PTAS) during sleep delivered via a wearable device to enhance slow-wave activity in sleep.

OTHER

Digital Cognitive Training (CogT)

All participants will complete a digital, home-based cognitive training (CogT) program following a standardized schedule.

Sponsors & Collaborators

  • University Hospital, Zürich

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Simon J. Schreiner, MD · University Hospital Zurich, University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-22
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441915 on ClinicalTrials.gov